U.S. warning on use of ‘march-in’ rights against Harvard seems like distant threat for pharma

Taking stock of the drug industry, from the lab to the medicine chest

August 14, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Charles Krupa/AP STAT+ | U.S. warning on use of 'march-in' rights against Harvard seems like distant threat for pharma Commerce Secretary Howard Lutnick's threat of march-in rights against Harvard University has put renewed focus on the Bayh-Dole Act. By Ed Silverman STAT+ | Eli Lilly says it will raise drug prices in Europe to 'make them lower' in U.S. The move could gain favor in the White House, but the impact on patients in U.S. and overseas remains unclear. By Elaine Chen and Daniel Payne STAT+ | Drugmakers form new group to lobby on impact of Medicare drug price negotiations The members of IRA Watchdog are Merck, AstraZeneca, Bristol Myers Squibb Company, and Eli Lilly, according to lobbying disclosure records. By John Wilkerson Adobe STAT+ | Trump administration leaves biotech investors more wary than ever of funding mRNA vaccines Life science investors say the Trump administration's retreat from mRNA vaccine funding is creating uncertainty for biotech firms. By Jonathan Wosen and Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser